Eva Blondeaux
Overview
Explore the profile of Eva Blondeaux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lambertini M, Blondeaux E, Tomasello L, Agostinetto E, Hamy A, Kim H, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401334.
PMID: 39993249
Purpose: To investigate the clinical behavior of breast cancer in young carriers according to the specific gene () and the association of the timing of genetic testing (before at diagnosis)...
2.
Perachino M, Blondeaux E, Molinelli C, Ruelle T, Giannubilo I, Arecco L, et al.
Eur J Clin Invest
. 2025 Feb;
:e70001.
PMID: 39943891
Background: Antibody-drug conjugates are novel effective therapies for metastatic breast cancer. Nevertheless, their toxicity profile can significantly affect patients' quality of life over time. Methods: This is a systematic review...
3.
Arecco L, Blondeaux E, Bruzzone M, Arpino G, De Angelis C, De Laurentiis M, et al.
J Natl Cancer Inst
. 2025 Feb;
PMID: 39908473
Background: The monarchE and NATALEE trials employed different high-risk inclusion criteria. Main objective is to assess prognostic differences based on their inclusion criteria. Methods: Patients with hormone receptor-positive/HER2-negative early breast...
4.
Cucciniello L, Blondeaux E, Bighin C, Gasparro S, Russo S, Dri A, et al.
NPJ Breast Cancer
. 2024 Dec;
10(1):105.
PMID: 39695115
This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the...
5.
Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, et al.
Eur J Cancer
. 2024 Nov;
213():115113.
PMID: 39536433
Purpose: The aim of this study was to evaluate the effectiveness of CDK 4/6 inhibitors (CDK 4-6i) according to HER2 status (low/zero), and endocrine resistance/sensitivity, as well as the efficacy...
6.
Boutros A, Diaz Gaitan N, Orengo G, Blondeaux E, Pastorino A, Zacconi M, et al.
Tumori
. 2024 Oct;
110(6):422-429.
PMID: 39370630
Background: Colon cancer imposes a significant burden on global healthcare systems, necessitating efforts to improve oncology care quality and patient outcomes. We studied the correlation between care quality and survival...
7.
Arecco L, Latocca M, Blondeaux E, Riccardi F, Mocerino C, Guarneri V, et al.
Breast
. 2024 Jul;
77:103769.
PMID: 39043079
Background: Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET). Patients And Methods: The Gruppo Italiano Mammella...
8.
Poggio F, Molinelli C, Giannubilo I, Lambertini M, Blondeaux E
Curr Opin Oncol
. 2024 Jul;
36(6):495-502.
PMID: 39011733
Purpose Of Review: Use of adjuvant chemotherapy significantly reduces the risk of recurrence and improves overall survival (OS) in patients with early-stage breast cancer. However, few data are available on...
9.
Giannubilo I, Battistuzzi L, Blondeaux E, Ruelle T, Poggio F, Buzzatti G, et al.
BMC Palliat Care
. 2024 May;
23(1):129.
PMID: 38778303
Objectives: To better understand the type of care offered to Italian patients with advanced breast cancer at the End-of-Life (EoL), we conducted a retrospective observational study. EoL was defined as...
10.
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim H, Di Meglio A, et al.
Cancer
. 2024 May;
130(16):2746-2762.
PMID: 38752572
Background: Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor...